Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes

PURPOSE: A 3-biomarker homologous recombination deficiency (HRD) score is a key component of a currently FDA-approved companion diagnostic assay to identify HRD in patients with ovarian cancer using a threshold score of ≥ 42, though recent studies have explored the utility of a lower threshold (GIS ...

Descripción completa

Detalles Bibliográficos
Autores principales: Lenz, Lauren, Neff, Chris, Solimeno, Cara, Cogan, Elizabeth S., Abramson, Vandana G., Boughey, Judy C., Falkson, Carla, Goetz, Matthew P., Ford, James M., Gradishar, William J., Jankowitz, Rachel C., Kaklamani, Virginia G., Marcom, P. Kelly, Richardson, Andrea L., Storniolo, Anna Maria, Tung, Nadine M., Vinayak, Shaveta, Hodgson, Darren R., Lai, Zhongwu, Dearden, Simon, Hennessy, Bryan T., Mayer, Erica L., Mills, Gordon B., Slavin, Thomas P., Gutin, Alexander, Connolly, Roisin M., Telli, Melinda L., Stearns, Vered, Lanchbury, Jerry S., Timms, Kirsten M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Original Laboratory Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504389/
https://www.ncbi.nlm.nih.gov/pubmed/37589839
http://dx.doi.org/10.1007/s10549-023-07046-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504389/
https://www.ncbi.nlm.nih.gov/pubmed/37589839
http://dx.doi.org/10.1007/s10549-023-07046-3

Ejemplares similares